A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes.

Conclusions For MBC patients who were previously treated with anthracyclines and/or taxanes, an irinotecan-containing regimen achieved moderate objective response and showed a trend of survival benefit, which deserves further study. irinotecan metastatic breast cancer efficacy chemotherapy palliative therapy National Key Research and Development Program of China 10.13039/501100012166 2017YFC0910004 West China Hospital, Sichuan University 10.13039/501100013365 ZYGD18012 Department of Science and Technology of Sichuan Province 10.13039/501100004829 2017FZ0062 Results of the univariate analysis indicated that the PFS of the irinotecan group was significantly prolonged in patients with visceral metastasis (P = 0.031) compared with those without visceral metastases.

also in 53,322 other papers